title: Role of endogenous GLP-1 and its agonists in osteopenia and osteoporosis: but we little know until tried.
abstract: The present brief review looks at the evidence on the role of GLP-1 and its agonists in osteopenia and osteoporosis in type 2 diabetes (T2DM). There is accumulating data to suggest a favourable effect of GLP-1 on bone metabolism. However, most data is from experimental studies, while clinical confirmation is still inadequate. Moreover, little is known on the precise mechanisms underlying these effects. Therefore, we need randomised clinical trials in T2DM patients to learn more on the action of GLP-1 on bone metabolism and its potential clinical implications.
authors: Athanasia
authors: A
authors: Papazafiropoulou
authors: Nikolaos
authors: N
authors: Papanas
authors: Stavros
authors: S
authors: Pappas
authors: Diabetes Centre, Third Department of Internal Medicine, General Hospital of Nikaia, Piraeus, Greece. pathan@ath.forthnet.gr.
authors: Efstratios
authors: E
authors: Maltezos
mesh_terms: D001851:Bone Diseases, Metabolic / Q000188:drug therapy / Q000378:metabolism*; D001842:Bone and Bones / Q000378:metabolism*; D002116:Calcitonin / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D000077270:Exenatide; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000819:agonists* / Q000378:metabolism*; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy / Q000378:metabolism*; D010455:Peptides / Q000627:therapeutic use; D018027:Receptors, Glucagon / Q000819:agonists / Q000378:metabolism*; D016896:Treatment Outcome; D014688:Venoms / Q000627:therapeutic use
chemical_list: C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D010455:Peptides; D018027:Receptors, Glucagon; D014688:Venoms; D052216:Glucagon-Like Peptide 1; D002116:Calcitonin; D000077270:Exenatide